Source - RNS
RNS Number : 4573J
Diurnal Group PLC
12 September 2016

12 September 2016



Diurnal Group plc

("Diurnal" or the "Company")


Notice of Final Results



Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will announce its financial results for the year ended 30 June 2016 on Wednesday, 12 October 2016.




Please further information, please visit or contact:


Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, CEO

Ian Ardill, CFO

Numis Securities Ltd

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam

Corporate Broking: James Black

FTI Consulting

+ 44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell



About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.  Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.


This information is provided by RNS
The company news service from the London Stock Exchange

Related Charts

Diurnal Group (DNL)

0.00p (0.00%)
delayed 14:00PM